Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women

被引:26
作者
Dias, AR
Melo, RN
Gebara, OCE
D'Amico, EA
Nussbacher, A
Halbe, HW
Pinotti, JA
机构
[1] Univ Sao Paulo, Sch Med, Dept Gynecol & Obstet, BR-05409001 Sao Paulo, Brazil
[2] Univ Sao Paulo, Sch Med, Inst Heart, InCor,Geriatr Cardiol Div, BR-05508 Sao Paulo, Brazil
[3] Hemoctr Sao Paulo, Pro Sangue Fdn, Lab Thrombosis, Sao Paulo, Brazil
关键词
conjugated estrogens; raloxifene; lipid profile; coagulation; fibrinolysis;
D O I
10.1080/13697130500042581
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objectives To compare the effect of conjugated equine estrogens (CEE) and raloxifene on lipid profile and hemostasis. Materials and methods A double-blind, randomized and parallel study was performed with 90 healthy postmenopausal women, aged 54 +/- 5 years, divided into three groups and submitted to daily therapy with either CEE 0.625 mg, raloxifene 60 mg or placebo for 4 months. The lipid profile, coagulation and fibrinolytic factors were analyzed. Results CEE increased the levels of high density lipoprotein cholesterol (HDL-C) from 49.0 to 56.8 mg/dl (p < 0.001), very low density lipoprotein cholesterol (VLDL-C) from 17.2 to 22.3 mg/dl (p < 0.001), and triglycerides from 86.0 to 111.7 mg/dl (P < 0.001.), and decreased the levels of low density lipoprotein cholesterol (LDL-C) from 121.0 to 106.5 mg/dl (p < 0.001). The only significant effect of raloxifene was an increase in the levels of HDL-C from 46.0 to 47.8 mg/dl (p = 0.019). There was no significant reduction in LDL-C, from 115.5 to 110.2 mg/dl (p=0.06), VLDL-C, from 21.7 to 20.0 mg/dl (p=0.201), and triglycerides, from 108 to 100 mg/dl (p=0.201). CEE decreased the levels of fibrinogen, from 370.5 to 326.8 g/l (p=0.039) and the levels of antithrombin III, from 99.5 to 93.2% (p < 0.001). Raloxifene decreased the levels of fibrinogen, from 354.7 to 302.0 g/l (p = 0.009) and the levels of antithrombin III, from 102.4 to 98.5% (p = 0.039). CEE increased levels of protein C from 103.7 to 115.3 mg/l (p < 0.001) and raloxifene did not change the levels of protein C (107.9 to 105.1 mg/l; p = 0.158). CEE decreased the antigen levels of tissue plasminogen activator (t-PA) from 8.8 to 6.8 U/ml (p < 0.001), and of plasminogen activator inhibitor (PAI-1) from 30.8 to 21.6 U/ml (p < 0.010), whereas raloxifene had no significant effect on either t-PA, from 9.6 to 9.2 U/ml (p = 0.235) or PAI-1 antigen levels, from 32.1 to 30.4 U/ml (p = 0.538).
引用
收藏
页码:63 / 70
页数:8
相关论文
共 38 条
[1]  
ALLAIN CC, 1974, CLIN CHEM, V20, P470
[2]   Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial [J].
Anderson, GL ;
Limacher, M ;
Assaf, AR ;
Bassford, T ;
Beresford, SAA ;
Black, H ;
Bonds, D ;
Brunner, R ;
Brzyski, R ;
Caan, B ;
Chlebowski, R ;
Curb, D ;
Gass, M ;
Hays, J ;
Heiss, G ;
Hendrix, S ;
Howard, BV ;
Hsia, J ;
Hubbell, A ;
Jackson, R ;
Johnson, KC ;
Judd, H ;
Kotchen, JM ;
Kuller, L ;
LaCroix, AZ ;
Lane, D ;
Langer, RD ;
Lasser, N ;
Lewis, CE ;
Manson, J ;
Margolis, K ;
Ockene, J ;
O'Sullivan, MJ ;
Phillips, L ;
Prentice, RL ;
Ritenbaugh, C ;
Robbins, J ;
Rossouw, JE ;
Sarto, G ;
Stefanick, ML ;
Van Horn, L ;
Wactawski-Wende, J ;
Wallace, R ;
Wassertheil-Smoller, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14) :1701-1712
[3]  
[Anonymous], CLIN CHEM
[4]  
[Anonymous], 1987, FUNDAMENTALS CLIN CH
[5]  
BERGSDORF N, 1983, THROMB HAEMOSTASIS, V50, P740
[6]   ROLE OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IN THE PATHOGENESIS AND OUTCOME OF THE HEMOLYTIC UREMIC SYNDROME [J].
BERGSTEIN, JM ;
RILEY, M ;
BANG, NU .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (11) :755-759
[7]  
Clarke M, 1998, LANCET, V351, P1451
[8]   A DOSE-RESPONSE RELATIONSHIP BETWEEN SEX HORMONE-INDUCED CHANGE IN HEPATIC TRIGLYCERIDE LIPASE AND HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL IN POSTMENOPAUSAL WOMEN [J].
COLVIN, PL ;
AUERBACH, BJ ;
CASE, LD ;
HAZZARD, WR ;
APPLEBAUMBOWDEN, D .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1991, 40 (10) :1052-1056
[9]   Risk of venous thromboembolism in users of hormone replacement therapy [J].
Daly, E ;
Vessey, MP ;
Hawkins, MN ;
Carson, JL ;
Gough, P ;
Marsh, S .
LANCET, 1996, 348 (9033) :977-980
[10]   Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women [J].
Delmas, PD ;
Bjarnason, NH ;
Mitlak, BH ;
Ravoux, AC ;
Shah, AS ;
Huster, WJ ;
Draper, M ;
Christiansen, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (23) :1641-1647